Argenx Se (ARGX) AI Stock Analysis

• Market Cap: $43.90B
• Dividend Yield: N/A
• Average Volume (3M): 355.58K
• Price to Earnings (P/E): 39.8
• Beta (1Y): 0.28
• Revenue Growth: 89.58%
• EPS Growth: N/A
• Country: US
• Employees: 1,599
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 8.02
• Shares Outstanding: 61,883,408
• 10 Day Avg. Volume: 449,666
• 30 Day Avg. Volume: 355,583
• PEG Ratio: 0.77
• Price to Book (P/B): 7.04
• Price to Sales (P/S): 12.38
• P/FCF Ratio: 61.05
• Enterprise Value/Market Cap: 0.92
• Enterprise Value/Revenue: 12.08
• Enterprise Value/Gross Profit: 13.58
• Enterprise Value/Ebitda: 31.10
• 1Y Price Target: $1,036.18
• Price Target Upside: 46.18% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 19
• EPS Forecast (FY): 26.77
• Revenue Forecast (FY): $5.94B

• Rating: 75 Outperform
• Price Target: $863.00 ▲(21.75% Upside)
• Action: Reiterated Date: 03/02/26
• Date: Action: Reiterated 03/02/26

Score is driven primarily by strong financial performance (rapid 2025 growth, high margins, and a very conservative balance sheet) and a constructive earnings-call outlook with meaningful label-expansion catalysts. Offsetting factors are weak near-term technical momentum and a premium valuation with no dividend support, plus execution risks from low reported gross margin and rising OpEx.

Positive Factors

Rapid, durable revenue growth

Sustained, large-scale commercial adoption of VYVGART (≈19,000 patients, broad prescriber base) drove 90% revenue growth in 2025. That scale supports durable cash generation, strengthens payer negotiations, funds reinvestment in commercial expansion and reduces reliance on financing over the medium term.

Very strong balance sheet and liquidity

Extremely low leverage and a multi-billion cash position provide long-term strategic optionality: ability to fund R&D, commercial rollouts, and M&A without material refinancing risk. This financial flexibility cushions execution risk and supports multi-year investment in pipeline and delivery modalities.

Clinical wins and label-expansion catalysts

Positive Phase 3 ocular MG data plus active regulatory filings (and an upcoming PDUFA for seronegative gMG) materially expand VYVGART’s addressable market. Successful label extensions and registrational momentum create durable revenue tailwinds and deepen the company’s neuromuscular franchise.

Negative Factors

Low reported gross margin

A low reported gross margin constrains incremental operating leverage as sales grow, limiting how much revenue growth converts to operating profit and free cash flow. Over 2–6 months this elevates sensitivity to pricing pressure, COGS variability, and could slow net margin expansion despite scale.

High and rising operating expenses

Elevated R&D and SG&A spending to support multiple programs and next‑gen assets creates persistent margin pressure. If commercial growth slows or new indications meet delays, sustained OpEx expansion could erode cash generation and require reprioritization of programs or additional financing.

Pipeline setbacks and regulatory burden

Clinical failures (ALS), the discontinuation of TED studies, and added regulatory demands (e.g., Graves requiring two trials) highlight development risk. Such attrition and extra trials increase costs, delay diversification of revenue streams, and concentrate near-term reliance on VYVGART launches and label expansions.

Argenx Se Business Overview & Revenue Model

Company Description

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

How the Company Makes Money

Argenx generates revenue through multiple streams, primarily focused on the commercialization of its therapeutic products. This includes revenue from product sales of its approved therapies, such as efgartigimod, which is marketed for the treatment of autoimmune disorders like myasthenia gravis. Additionally, the company engages in strategic partnerships and collaborations with other pharmaceutical firms, which often involve upfront payments, milestone payments upon achieving certain development or regulatory goals, and royalties on net sales of products developed under these collaborations. These partnerships not only provide financial resources but also enhance Argenx's capabilities in research and development, ultimately contributing to its overall earnings.

Argenx Se Financial Statement Overview

Summary

Breakout 2025 results with sharp revenue acceleration ($4.16B, +81.5% YoY) and strong profitability (gross margin ~89%, operating margin ~23%, net margin ~31%). Balance sheet is exceptionally strong with minimal leverage (debt-to-equity ~0.01) and a large equity base, but cash-flow durability is a watch item given uneven history (negative OCF/FCF in 2021–2024) despite strong 2025 improvement.

Income Statement

ARGX shows a sharp profitability inflection: revenue accelerated meaningfully into 2025 ($4.16B, +81.5% YoY) after strong expansion from 2022–2024, and margins are exceptionally strong for the industry (2025 gross margin ~89%, operating margin ~23%, net margin ~31%). Results also show improved operating discipline versus prior-year losses (2022–2023), though the earnings profile has been volatile over the cycle and includes a period where operating profit lagged reported net income (2024 had slightly negative operating profit despite positive net income).

Balance Sheet

The balance sheet is a major strength: leverage is extremely low (2025 debt-to-equity ~0.01) with a large and growing equity base ($7.32B) and asset base ($8.68B). Returns on equity improved alongside profitability (2025 ROE ~17.7% vs. negative in 2021–2023), providing flexibility to fund R&D and commercialization; the key watchout is that the business has historically relied on external capital during loss-making years, so maintaining profitability is important to preserve this strength.

Cash Flow

Cash flow quality improved materially in 2025, with solid positive operating cash flow (~$850M) and free cash flow (~$844M) alongside strong free-cash-flow growth (~78%). However, the cash flow record is uneven: operating and free cash flow were negative in 2021–2024, and in 2025 operating cash flow covered only about two-thirds of net income, indicating earnings-to-cash conversion is not yet consistently strong across periods.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	4.16B	2.19B	1.23B	410.75M	497.28M
Gross Profit	3.71B	1.96B	1.11B	381.31M	497.28M
EBITDA	972.46M	105.17M	-192.28M	-622.78M	-392.78M
Net Income	1.30B	833.04M	-295.05M	-709.59M	-407.63M
Balance Sheet
Total Assets	8.68B	6.20B	4.54B	3.13B	2.85B
Cash, Cash Equivalents and Short-Term Investments	4.44B	3.38B	3.18B	2.19B	2.34B
Total Debt	83.49M	39.05M	20.00M	12.43M	11.46M
Total Liabilities	1.36B	704.24M	444.95M	320.56M	316.05M
Stockholders Equity	7.32B	5.50B	4.10B	2.81B	2.53B
Cash Flow
Free Cash Flow	844.30M	-151.05M	-464.14M	-966.63M	-728.25M
Operating Cash Flow	850.49M	-82.75M	-420.33M	-862.81M	-606.81M
Investing Cash Flow	823.88M	-717.59M	308.21M	-461.18M	-347.07M
Financing Cash Flow	233.73M	279.76M	1.34B	843.76M	1.12B

Argenx Se Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 708.85
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARGX, the sentiment is Negative. The current price of 708.85 is below the 20-day moving average (MA) of 783.95, below the 50-day MA of 807.90, and below the 200-day MA of 746.60, indicating a bearish trend. The MACD of -29.27 indicates Positive momentum. The RSI at 28.61 is Positive, neither overbought nor oversold. The STOCH value of 24.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ARGX.

Argenx Se Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
REGN	81 Outperform	$78.92B	17.92	14.83%	0.45%	2.89%	0.50%
ARGX	75 Outperform	$43.90B	39.77	16.82%	―	89.58%	―
INCY	75 Outperform	$18.32B	14.98	29.15%	―	18.09%	3563.21%
GMAB	66 Neutral	$16.53B	19.82	14.32%	―	24.98%	127.06%
ALNY	57 Neutral	$42.07B	166.04	90.35%	―	53.24%	―
BNTX	57 Neutral	$22.64B	-17.95	-3.04%	―	7.04%	-25.24%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Argenx Se Corporate Events

Argenx Posts First Operating Profit on Surging VYVGART Sales and Expanding Autoimmune Pipeline

On February 26, 2026, Argenx reported that 2025 marked its first year of operating profitability, delivering $4.2 billion in global product net sales, up 90% year over year, and $1.1 billion in operating income, driven by rapid uptake of VYVGART and expansion to about 19,000 patients worldwide. The company also highlighted positive Phase 3 ADAPT OCULUS data in ocular myasthenia gravis, ongoing regulatory review for seronegative generalized MG, and a broad late-stage pipeline that is expected to yield four Phase 3 molecules and multiple new clinical candidates by the end of 2026, underpinning its Vision 2030 growth strategy and reinforcing its leadership in FcRn‑based therapies.

Argenx outlined a series of upcoming milestones, including planned label expansions for VYVGART into ocular MG and additional MG populations, registrational studies in rheumatology and Graves’ disease, and Phase 3 programs for empasiprubart in MMN and CIDP and adimanebart in congenital myasthenic syndromes. While discontinuing adimanebart development in ALS following Phase 2a data, the company is advancing next‑generation FcRn assets, autoinjector delivery, and several first‑in‑class molecules, positioning the business for sustained growth and deeper penetration of autoimmune markets over the next several years.

The most recent analyst rating on (ARGX) stock is a Buy with a $1008.00 price target. To see the full list of analyst forecasts on Argenx Se stock, see the ARGX Stock Forecast page.

Argenx Reports Positive Phase 3 VYVGART Data in Ocular Myasthenia Gravis

On February 26, 2026, Argenx reported positive topline Phase 3 results from its ADAPT OCULUS trial of subcutaneous VYVGART in adults with ocular myasthenia gravis, the first registrational study focused specifically on this under-served form of the disease. The trial met its primary endpoint, showing statistically significant improvement in patient-reported ocular symptoms versus placebo, with meaningful reductions in diplopia and ptosis and a safety profile consistent with prior studies.

Argenx said the data will support a planned supplemental biologics application to U.S. regulators to expand the VYVGART label into ocular myasthenia gravis, potentially broadening use of its core asset and reinforcing its positioning in the myasthenia gravis treatment landscape. The results underscore a significant unmet need in ocular MG, and, if approved, could extend targeted therapy access to a wider segment of MG patients and strengthen Argenx’s neuromuscular franchise.

The most recent analyst rating on (ARGX) stock is a Buy with a $1008.00 price target. To see the full list of analyst forecasts on Argenx Se stock, see the ARGX Stock Forecast page.

argenx Wins FDA Priority Review for VYVGART in Seronegative gMG

On January 13, 2026, argenx SE announced that the U.S. Food and Drug Administration accepted for priority review its supplemental Biologics License Application for intravenous VYVGART (efgartigimod alfa-fcab) to treat adults with acetylcholine receptor antibody seronegative generalized myasthenia gravis, a patient group with high unmet need and no approved options for certain subtypes. The filing, backed by positive Phase 3 ADAPT SERON data showing statistically significant and clinically meaningful improvements in disease activity and a safety profile consistent with prior use, sets a Prescription Drug User Fee Act target action date of May 10, 2026, positioning argenx to potentially broaden VYVGART’s label, strengthen its foothold in the gMG market, and expand its addressable patient population if approval is granted.

The most recent analyst rating on (ARGX) stock is a Hold with a $900.00 price target. To see the full list of analyst forecasts on Argenx Se stock, see the ARGX Stock Forecast page.

argenx Posts 90% Sales Surge and Maps Pivotal 2026 Pipeline, Leadership Transition

On January 12, 2026, argenx reported preliminary 2025 global product net sales of $4.15 billion, a 90% year-on-year increase driven by VYVGART, which is now used by roughly 19,000 patients worldwide, and outlined a 2026 plan centered on expanding VYVGART’s use and label, advancing its FcRn franchise, and accelerating its broader immunology pipeline. The company highlighted a pivotal year ahead with four registrational readouts in 2026, including the first Phase 3 data for its C2 antibody empasiprubart, multiple Phase 3 milestones across myasthenia gravis, ITP and rheumatology, and the planned start of additional registrational and early-stage studies that together position argenx for potential new product launches from 2027 onward; it also flagged an upcoming leadership transition, with COO Karen Massey set to become CEO and current CEO Tim Van Hauwermeiren moving to non-executive chairman, underscoring both operational momentum and a managed governance handover for investors and patients.

The most recent analyst rating on (ARGX) stock is a Buy with a $1091.00 price target. To see the full list of analyst forecasts on Argenx Se stock, see the ARGX Stock Forecast page.

Argenx Unveils CEO Succession as Co‑Founder Moves to Chair Role

On January 5, 2026, Argenx SE announced a planned leadership transition designed to support its next phase of growth, highlighted by the promotion of Chief Operating Officer Karen Massey to Chief Executive Officer and Executive Director and the move of co-founder and current CEO Tim Van Hauwermeiren to non-executive director and Chairman of the Board, succeeding long-serving chair Peter Verhaeghe, who will retire after serving since 2008. The changes, which remain subject to shareholder approval at the company’s annual general meeting on May 6, 2026, signal a continuity-focused succession that keeps Van Hauwermeiren closely involved in long-term strategy and innovation while elevating Massey, credited with accelerating the launch of flagship product VYVGART and building the company’s commercial engine, to steer execution of Argenx’s Vision 2030 and future expansion, with implications for sustained strategic stability and stakeholder confidence in its growth trajectory.

The most recent analyst rating on (ARGX) stock is a Hold with a $858.00 price target. To see the full list of analyst forecasts on Argenx Se stock, see the ARGX Stock Forecast page.

argenx Discontinues Phase 3 UplighTED Studies for Thyroid Eye Disease

On December 15, 2025, argenx SE announced the discontinuation of its Phase 3 UplighTED studies evaluating efgartigimod SC in adults with moderate to severe thyroid eye disease (TED) due to futility, as recommended by an Independent Data Monitoring Committee. Despite the trials not meeting desired outcomes, efgartigimod demonstrated a favorable safety profile. The company plans to conduct a comprehensive analysis of the data to gain insights for future research in TED. This decision reflects argenx’s commitment to responsible resource management in its clinical development programs.

The most recent analyst rating on (ARGX) stock is a Buy with a $1316.00 price target. To see the full list of analyst forecasts on Argenx Se stock, see the ARGX Stock Forecast page.